ArticleThe Journal of antibiotics2026
Bortezomib exhibited bacteriostatic activity and pro-inflammatory effect against Mycoplasma pneumoniae.
Article in The Journal of antibiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae (MP) is an important respiratory pathogen. Growth inhibition and regulation of inflammation in lung are key to the treatment of MP infections. Bortezomib, a proteinase inhibitor, was found to possess both functions in this study. Firstly, bortezomib showed dose-dependent bacteriostatic activity against MP in culture medium. Decreases in glucose catabolism (changes of pH) and colony-forming units (CFUs) were detected at 3 d post-incubation (bortezomib>10 nM). The MP cells incubated with bortezomib of 25 nM exhibited decreases in contents of protein and carbohydrate comparing to normal MP cells. When co-incubated with lung epithelial cells, reductions in MP CFUs and viability of lung epithelial cells were detected. Transcriptome analysis revealed that bortezomib (25 nM) influence the protein digestion and absorption pathways in A549 cells. Meanwhile, bortezomib up-regulated the PI3K-Akt and JAK-STAT pathways and down-regulated the MAPK pathway in MP-infected cells. Western-blot detection revealed that bortezomib reduce the increase in TLR4 triggered by MP, and reduce the level of IκBα. Meanwhile, higher level of extracellular IL-6 was detected in MP-infected cells post bortezomib treatment. In addition, the secretions of bortezomib-treated A549 cells showed promoting effects on M1-polarization of macrophages. In Balb/c mice, oral administration of bortezomib promoted the production of MP-specific antibodies and reduced pulmonary damage at 7th day post infection. In conclusion, bortezomib exerts a direct bacteriostatic effect on MP in vitro, it also plays roles in the regulation of inflammatory pathways during MP infection.
Indexed as
Identifiers
42432374What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.